: Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. : We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. : We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was -75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0-1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. : LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10744599 | PMC |
http://dx.doi.org/10.3390/medicina59122196 | DOI Listing |
J Clin Apher
February 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Pediatr Blood Cancer
January 2025
Department of Audiology and Speech Therapy, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Introduction: Sickle cell anemia has a genetic origin characterized by an autosomal recessive inheritance pattern. The nervous system may be subject to vaso-occlusion and, consequently, affect the proper functioning of the central portion of hearing.
Objective: To assess central auditory skills and analyze short- and long-latency auditory evoked potentials in children with sickle cell disease.
Neurol Sci
January 2025
Hematology Unit, Careggi University Hospital, Florence, Italy.
Background: The coexistence of sickle cell anemia and multiple sclerosis in a single patient presents a rare and challenging clinical scenario, possibly favoured by the interplay between chronic inflammatory states and autoimmune processes.
Methos/results: We present the case of a 36-year-old woman with sickle cell anemia who developed progressive neurological symptoms leading to frequent falls and paraparesis; magnetic resonance imaging showed many periventricular, infratentorial, and both cervical and dorsal spinal cord lesions, leading to a diagnosis of multiple sclerosis. After a multidisciplinary approach the patient was successfully started on ofatumumab.
J Nurs Adm
January 2025
Author Affiliations: Nursing Research Consultant (Dr Feetham), Nurse Scientist, and Associate Professor, George Washington University School of Medicine, Washington, DC (Dr Kelly), Nursing Research and Development Programs Manager (Dr Engh), Department Nursing Science, Professional Practice Quality, Director Healthcare Consulting CBRE Washington DC (Dr Frame): Chief Nursing Informatics and Education Officer (Dr King), Nurse Practitioner, Psychiatry Consult Liaison Service (Dr Ojini), Division of Emergency Medicine and Trauma Nursing Director (Dr Schultz), Sickle Cell Disease Lead Translation Research Advanced Practice Nurse and Director of the Sickle Cell Disease Transition Clinic, Associate Professor George Washington University (Dr Barbara Speller-Brown), and Simulation Program Manager (Dr Walsh), Children's National Hospital, Washington, DC; and Assistant Professor (Dr Giordano), Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.
Advancing nursing practice to improve care and system outcomes requires doctoral-prepared nurses to conduct programs of research and translate science to practice. The authors describe a Doctoral support group (DSG) at one hospital designed to support nurses considering and navigating doctoral education while continuing as hospital employees. Strategies from 18 years' experience are provided for others to develop and sustain a DSG as part of an environment to support and retain nurses with doctoral degrees.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!